期刊文献+

伐地那非衍生物的合成和体内活性评价 被引量:3

Synthesis of Vardenafil Analogue and Its Activity Evaluation in vivo
下载PDF
导出
摘要 首次完成了伐地那非衍生物——2-[2-乙氧基-5-(4-乙基-哌嗪-1-磺酰基)-吡啶]-5-甲基-7-丙基-3H-咪唑[5,1-f]-三嗪-4-酮(1)的合成,并且对其进行了家兔阴茎勃起的体内实验,结果表明该化合物无壮阳作用. The first synthesis of a Vardenafil analogue 1-methyl-3-prepyl-5-[2-[2-ethoxy-5-(4-ethyl piperazinosulfonyl)-3-pyddyl]-6H-imidazo[1,5-f]-1',2',4'-triazin-7-one (1) was achieved, and compound 1 was evaluated by the erections in rabbits in vivo which exhibited no potency to the treatment of erectile dysfunction.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2007年第24期2917-2922,共6页 Acta Chimica Sinica
关键词 磷酸二酯酶5抑制剂 伐地那非 咪唑并三嗪 男性勃起功能障碍 phosphodiesterase 5 inhibitor vardenafil imidazotriazine male erectile dysfunction
  • 相关文献

参考文献14

  • 1Saenz de Tejada, I. Contemp. Urol. 1992, 7, 52.
  • 2Andersson, K. E.; Wager, G. Physiol. Rev. 1995, 75, 191.
  • 3Moreland, R. B.; Goldstein, I.; Kim, N. N.; Traish, A. Trends. Endicrinol. Metab. 1999, 10, 97.
  • 4Martel, A. M.; Graul, A.; Rabasseda, X.; Castaner, R. Drugs Future 1997, 22, 138.
  • 5Terret, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Bioorg. Med. Chem. Lett. 1996, 6, 1819.
  • 6Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.; Naylor, A. M.; Osterloh, I. H.; GingeU, C. Int. J. Urol. Res. 1996, 8, 47.
  • 7Corbin, J.-D. Int. J. lmpot. Res. 2004, 16, 4.
  • 8Bischoff, E. Int. J. lmpot. Res. 2004, 16, 11.
  • 9Bischoff, E.; Mondritzki, T.; Niewoehner, U.; Haning, H.; Zimmer, D. In 5th Congress of the European Society or Sexual and Impotence Research, Hamburg, Dec. 1, 2002.
  • 10Kim, D. K.; Ryu, D. H.; Lee, N.; Lee, J. Y.; Kim, J. S.; Lee, S.; Choi, J. Y.; Ryu, J. H.; Kim, N. H.; Ira, G. J.; Choi, W. S.; Kim, T. K. Bioorg. Med. Chem. 2001, 9, 1895.

同被引文献30

  • 1向红琳,胡高云,刘丰贤,李树华,姜素芳.枸橼酸西地那非合成工艺改进[J].湖南师范大学学报(医学版),2000(1):47-48. 被引量:3
  • 2沈周俊,余燕岚.5型磷酸二酯酶抑制剂治疗勃起功能障碍的疗效和安全性[J].中华男科学杂志,2005,11(8):631-634. 被引量:17
  • 3Stark S,Sachse R,Liedl T,et al.Vardenafil increase penile rigidity and tumescence in men with erectile dysfunction after single oral dose[J].Eur Urol,2001,40(2) : 181-184.
  • 4Porst H,Young JM, Schmidt A. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups[J].Urology, 2003,62 (3) : 519-522.
  • 5Hamilton HW, Ortwine DF, Worth DF,et al. Synthesis and structure-activity relationships of pyrazolo [4,3-d]pyrim- idin-7-ones as adenosine receptor antagonists [J].J Med Chem, 1987,30(1 ) :91-96.
  • 6Bell A, Brown D, Terrett N K. Pyracolopyrinidinone agents : EP 463 756 [ P]. 1991.
  • 7Boolell M, Allen M J, Ballard S A, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodi- esterase inhibitor for the treatment of penile erectile dysfunction [ J ]. Int J Impot Res, 1996,8 ( 2 ) :47 - 52.
  • 8Corbin J D, Francis S H. Cyclic GMP phosphodiester- ase-5 : Target of sildenafil [ J ]. J Biol Chem, 1999,274 (20) : 13729 - 13732.
  • 9何鹏飞,张培福,丁以绚.西地那非研究进展[J].中国医学科学院学报,1999,12(6):493-495.
  • 10Venhuis B J, Zomer G, de Kaste D. Structure eluci- dation of a novel synthetic thiono analogue of sildenafil detected in an alleged herbal aphrodisiac [ J ]. J Pharm Biomed Anal,2008.46 (4) : 814 - 817.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部